-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Pharmaceutical Guanlan
On June 22, Jun Shengtai announced that it will demonstrate HTD1801 in the treatment of primary sclerosis at the annual meeting of the European Society for the Study of the Liver (EASL) and the International Conference on Liver Diseases (ILC 2021) to be held from June 23 to 26, 2021.
Public information shows that HTD1801 is an oral multifunctional small molecule drug independently developed by Junshengtai.
Primary sclerosing cholangitis is a chronic progressive liver disease characterized by inflammation and fibrosis of the bile ducts, which in turn causes multifocal bile duct stenosis
In this clinical trial, 55 adult PSC patients were randomly assigned to HTD1801 (500mg, 1,000mg) or placebo, administered twice a day (BID), and after 6 weeks, each group was evaluated for alkaline phosphatase (ALP) The reduction level
Currently, HTD1801 is simultaneously developing primary sclerosing cholangitis, primary biliary cholangitis (PBC), non-alcoholic steatohepatitis with type 2 diabetes (NASH + T2DM), type 2 diabetes and its complications globally And other indications
Note: The original text has been deleted
Reference materials:
[1] Jun Shengtai will present the results of the Phase II clinical trial of HTD1801 in the treatment of primary sclerosing cholangitis.
